A61K 40/35
Cytokines
A61K40/35 (Cytokines) appears on 57 US grants and 322 published applications in this corpus.
Search patents in A61K- Granted patents
- 57
- Published applications
- 322
- Assignees
- 179
- Inventors
- 882
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 1 |
| 2002 | 0 | 3 |
| 2003 | 0 | 2 |
| 2004 | 0 | 7 |
| 2005 | 0 | 2 |
| 2006 | 1 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 2 |
| 2009 | 0 | 5 |
| 2010 | 1 | 1 |
| 2011 | 1 | 1 |
| 2012 | 0 | 1 |
| 2013 | 1 | 4 |
| 2014 | 1 | 2 |
| 2015 | 1 | 2 |
| 2016 | 1 | 3 |
| 2017 | 2 | 4 |
| 2018 | 0 | 3 |
| 2019 | 1 | 1 |
| 2020 | 3 | 20 |
| 2021 | 5 | 19 |
| 2022 | 4 | 21 |
| 2023 | 6 | 37 |
| 2024 | 7 | 66 |
| 2025 | 12 | 65 |
| 2026 | 9 | 49 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions, devices and methods for inducing immune responses to infectious agents16 Jun 2026US 12,653,888 B2Sigilon Therapeutics, Inc.
- CA2-IL15 fusion proteins for tunable regulation2 Jun 2026US 12,642,792 B2Obsidian Therapeutics, Inc.
- Methods and compositions for reducing the immunogenicity of chimeric notch receptors5 May 2026US 12,617,825 B2Cell Design Labs, Inc.
- Genetically modified immune cell, preparation method therefor, and application5 May 2026US 12,617,828 B2Shenzhen In Vivo Biomedicine Technology Limited Company
- Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies24 Mar 2026US 12,584,138 B2ImmunityBio, Inc.
- Multi-receptor natural killer cells8 Oct 2026US 2026/0308225 A1Board of Regents, The University of Texas System
- Switch receptors1 Oct 2026US 2026/0295042 A1Hoffmann-La Roche Inc.
- Rna replicons, compositions and methods of use thereof24 Sep 2026US 2026/0286321 A1Able Sciences, Inc.
- Methods of evading immune rejection17 Sep 2026US 2026/0273059 A1
- Multi-receptor natural killer cells17 Sep 2026US 2026/0275288 A1Board of Regents, The University of Texas System
Most cited
By later US patents
- Interleukin 15 as selectable marker for gene transfer in lymphocytes43US 9,487,800 B2Chemotherapeutisches Forschunginstitut Georg-Speyer-Haus · 2016
- Method for producing T.sub.H -independent cytotoxic T lymphocytes36US 5,470,730 AFred Hutchinson Cancer Research Center · 1995
- Adoptive immunotherapy with enhanced T lymphocyte survival28US 7,998,736 B2The United States of America as represented by the Department of Health and Human Services · 2011
- Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies13US 10,960,024 B2NantKwest, Inc. · 2021
- Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-expressing NK cells12US 11,077,143 B2NantKwest, Inc. · 2021